Back to results
US 2006/0217360 A1Published application
Tubulysin biosynthesis gene
OwnerGerhard Hoefle, Rolf Mueller +3inventors
InventorsGerhard Hoefle, Rolf Mueller, Florenz Sasse, Axel Sandmann, Helmut Bloecker
Life of this patent
Estimating the term…
Abstract
The invention relates to an ssDNA molecule, to a dsDNA molecule, to an RNA, to a vector, to the use thereof and to a cell, especially for the expression of tubulysin genes.
Claims34
An ssDNA molecule selected from the following group:
- (i) an ssDNA molecule having a sequence according to FIG. 1;
- (ii) an ssDNA molecule which is 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% homologous to an ssDNA molecule according to (i) in respect of its number of nucleotides or its nucleotide sequence but which differs by at least one nucleotide from the ssDNA molecule according to (i) in respect of its number of nucleotides and/or its nucleotide sequence;
- and
- (iii) an ssDNA molecule having a sequence which is complementary to the sequence of an ssDNA molecule according to (i) or (ii).
1 more element
An ssDNA molecule selected from the following group:
- (i) am ssDNA molecule having a sequence of positions 3.308 to 1 (ORF 16) of the sequence according to FIG. 1;
- (ii) an ssDNA molecule having a sequence of positions 4706 to 3453 (ORF 15) of the sequence according to FIG. 1;
- (iii) an ssDNA molecule having a sequence of positions 5719 to 7164 (ORF 14) of the sequence according to FIG. 1;
- (iv) an ssDNA molecule having a sequence of positions 9557 to 7317 (ORF 13) of the sequence according to FIG. 1;
- (v) an ssDNA molecule having a sequence of positions 12193 to 10550 (ORF 12) of the sequence according to FIG. 1;
- (vi) an ssDNA molecule having a sequence of positions 12841 to 13881 (ORF 11) of the sequence according to FIG. 1;
- (vii) an ssDNA molecule having a sequence of positions 14833 to 13835 (ORF 10) of the sequence according to FIG. 1;
- (viii) an ssDNA molecule having a sequence of positions 14942 to 15586 (ORF 9) of the sequence according to FIG. 1;
- (ix) an ssDNA molecule having a sequence of positions 15847 to 16983 (ORF 8) of the sequence according to FIG. 1;
- (x) an ssDNA molecule having a sequence of positions 21154 to 18809 (ORF 7) of the sequence according to FIG. 1;
- (xi) an ssDNA molecule having a sequence of positions 22366 to 23532 (ORF 6) of the sequence according to FIG. 1;
- (xii) an ssDNA molecule having a sequence of positions 24591 to 26513 (ORF 5) of the sequence according to FIG. 1;
- (xiii) an ssDNA molecule having a sequence of positions 26597 to 27517 (ORF 4) of the sequence according to FIG. 1;
- (xiv) an ssDNA molecule having a sequence of positions 29858 to 30400 (ORF 3) of the sequence according to FIG. 1;
- (xv) an ssDNA molecule having a sequence of positions 31220 to 32392 (TubA) of the sequence according to FIG. 1;
- (xvi) an ssDNA molecule having a sequence of positions 33056 to 32397 (ORF 2) of the sequence according to FIG. 1;
- (xvii) an ssDNA molecule having a sequence of positions 34195 to 33074 (TubZ) of the sequence according to FIG. 1;
- (xviii) an ssDNA molecule having a sequence of positions 35422 to 34205 (ORF 1) of the sequence according to FIG. 1;
- (xix) an ssDNA molecule having a sequence of positions 35522 to 40147 (TubB) of the sequence according to FIG. 1;
- (xx) an ssDNA molecule having a sequence of positions 40144 to 48021 (TubC) of the sequence according to FIG. 1;
- (xxi) an ssDNA molecule having a sequence of positions 48011 to 58558 (TubD) of the sequence according to FIG. 1;
- (xxii) an ssDNA molecule having a sequence of positions 58551 to 62096 (TubE) of the sequence according to FIG. 1;
- (xxiii) an ssDNA molecule having a sequence of positions 62103 to 70616 (TubF) of the sequence according to FIG. 1;
- (xxiv) an ssDNA molecule which is hybridisable with a molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), or (xxiii) under stringent conditions and especially has the same number of bases;
- and;
- (xxv) an ssDNA molecule which is 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% homologous to an ssDNA molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), or (xxiii) in respect of its number of nucleotides or its nucleotide sequence but which differs by at least on nucleotide from that ssDNA molecule in respect of its number of nucleotides and/or its nucleotide sequence;
- and
- (xxvi) an ssDNA molecule having a sequence which is complementary to the sequence of a molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), (xxiv) or (xxv).
25 more elements
An ssDNA molecule selected from the following group:
- (i) an ssDNA molecule having a sequence of positions 35747 to 36769 (domain C of the tubB gene) of the sequence according to FIG. 1;
- (ii) an ssDNA molecule having a sequence of positions 37184 to 39817 (domain A of the tubB gene) of the sequence according to FIG. 1;
- (iii) an ssDNA molecule having a sequence of positions 38369 to 39730 (domain NMT of the tubB gene) of the sequence according to FIG. 1;
- (iv) an ssDNA molecule having a sequence of positions 39818 to 40069 (domain PCP of the tubB gene) of the sequence according to FIG. 1;
- (v) an ssDNA molecule having a sequence of positions 40372 to 41397 (domain C of the tubC gene) of the sequence according to FIG. 1;
- (vi) an ssDNA molecule having a sequence of positions 41824 to 43215 (domain PCP of the tubC gene) of the sequence according to FIG. 1;
- (vii) an ssDNA molecule having a sequence of positions 43216 to 43461 (domain PCP of the tubC gene) of the sequence according to FIG. 1;
- (viii) an ssDNA molecule having a sequence of positions 43552 to 44574 (domain C of the tubC gene) of the sequence according to FIG. 1;
- (ix) an ssDNA molecule having a sequence of positions 44980 to 47631 (domain A of the tubC gene) of the sequence according to FIG. 1;
- (x) an ssDNA molecule having a sequence of positions 46153 to 47547 (domain NMT of the tubC gene) of the sequence according to FIG. 1;
- (xi) an ssDNA molecule having a sequence of positions 47632 to 47868 (domain PCP of the tubC gene) of the sequence according to FIG. 1;
- (xii) an ssDNA molecule having a sequence of positions 48011 to 49321 (domain KS of the tubD gene) of the sequence according to FIG. 1;
- (xiii) an ssDNA molecule having a sequence of positions 49622 to 50584 (domain AT of the tubD gene) of the sequence according to FIG. 1;
- (xiv) an ssDNA molecule having a sequence of positions 51473 to 52309 (domain KR of the tubD gene) of the sequence according to FIG. 1;
- (xv) an ssDNA molecule having a sequence of positions 53066 to 53980 (domain ER of the tubD gene) of the sequence according to FIG. 1;
- (xvi) an ssDNA molecule having a sequence of positions 54158 to 54460 (domain ACP of the tubD gene) of the sequence according to FIG. 1;
- (xvii) an ssDNA molecule having a sequence of positions 54461 to 55870 (domain HC of the tubD gene) of the sequence according to FIG. 1;
- (xviii) an ssDNA molecule having a sequence of positions 56000 to 57412 (domain A of the tubD gene) of the sequence according to FIG. 1;
- (xix) an ssDNA molecule having a sequence of positions 57413 to 57643 (domain PCP of the tubD gene) of the sequence according to FIG. 1;
- (xx) an ssDNA molecule having a sequence of positions 58689 to 59714 (domain C of the tubE gene) of the sequence according to FIG. 1;
- (xxi) an ssDNA molecule having a sequence of positions 60156 to 61697 (domain A of the tubE gene) of the sequence according to FIG. 1;
- (xxii) an ssDNA molecule having a sequence of positions 61698 to 61967 (domain PCP of the tubE gene) of the sequence according to FIG. 1;
- (xxiii) an ssDNA molecule having a sequence of positions 62127 to 63320 (domain KS of the tubF gene) of the sequence according to FIG. 1;
- (xxiv) an ssDNA molecule having a sequence of positions 63711 to 64676 (domain AT of the tubF gene) of the sequence according to FIG. 1;
- (xxv) an ssDNA molecule having a sequence of positions 64959 to 65882 (domain KR of the tubF gene) of the sequence according to FIG. 1;
- (xxvi) an ssDNA molecule having a sequence of positions 65985 to 67061 (domain CMT of the tubF gene) of the sequence according to FIG. 1;
- (xxvii) an ssDNA molecule having a sequence of positions 67242 to 67829 (domain DH of the tubF gene) of the sequence according to FIG. 1;
- (xxviii) an ssDNA molecule having a sequence of positions 68247 to 69128 (domain ER of the tubF gene) of the sequence according to FIG. 1;
- (xxix) an ssDNA molecule having a sequence of positions 69360 to 69605 (domain PCP of the tubF gene) of the sequence according to FIG. 1;
- (xxx) an ssDNA molecule having a sequence of positions 69759 to 70586 (domain TE of the tubF gene) of the sequence according to FIG. 1;
- (xxxi) an ssDNA molecule which is hybridisable with a molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), (xxiv), (xxv), (xxvi), (xxvii), (xxviii), (xxix) or (xxx) under stringent conditions and especially has the same number of bases;
- (xxxii) an ssDNA molecule which is 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% homologous to an ssDNA molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), (xxiv), (xxv), (xxvi), (xxvii), (xxviii), (xxix) or (xxx) in respect of its number of nucleotides or its nucleotide sequence but which differs by at least one nucleotide from that ssDNA molecule in respect of its number of nucleotides and/or its nucleotide sequence;
- and
- (xxxiii) an ssDNA molecule having a sequence which is complementary to the sequence of a molecule according to (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), (xxiv), (xxv), (xxvi), (xxvii), (xxviii), (xxix), (xxx), (xxxi) or (xxxii).
31 more elements
A polynucleotide comprising a sequence as defined in SEQ ID NO:
- 1, 18, 33 or 36, or a fragment thereof.
A polypeptide comprising at least one sequence as defined in SEQ ID NO:
- 2 to 17, 19 to 32, 34, 35, 37 and/or 38 and/or a fragment and/or derivative thereof.
Use of at least one polynucleotide as defined in SEQ ID NO:
- 1, 18, 33 and/or 36 and/or at least one fragment thereof and/or at least one polypeptide as defined in SEQ ID NO:
- 2 to 17, 19 to 32, 34, 35, 37 and/or 38 and/or at lease one fragment thereof in the production of a pharmaceutical composition for the treatment of undesirable cell growth or undesirable cell proliferation in an individual.
A pharmaceutical composition comprising at least one polynucleotide as defined in SEQ ID NO:
- 1, 18, 33 and/or 36 and/or at least one fragment thereof and/or at least one polypeptide as defined in SEQ ID NO:
- 2 to 17, 19 to 32, 34, 35, 37 and/or 38 and/or at least one fragment thereof.
A method of producing tubulysins and tubulysin biosynthesis proteins, comprising the steps:
- (a) expression of at least one polynucleotide as defined in SEQ ID NO:
- 1, 18, 33 and/or 36 and/or at least one fragment thereof and/or at least one polypeptide as defined in SEQ ID NO:
- 2 to 17, 19 to 32, 34, 35, 37 and/or 38 and/or at least one fragment thereof, and
- (b) purification of the expression products.
1 more element
A method of finding genes which are involved in the biosynthesis of tubulysins, comprising the steps:
- (a) hybridization of at least one polynucleotide as defined in SEQ ID NO:
- 1, 18, 33 and/or 36 and/or at least one fragment therof with DNA, RNA and/or cDNA of a species that is not identical to Angiococcus disciformis, and
- (b) isolation and characterization of the hybridized DNA, RNA and/or cDNA.
Use of a composition comprising at least one polypeptide as defined in SEQ ID NO:
- 2 to 17, 19 to 32, 34, 35, 37 and/or 38 and/or at least one biologically active fragment or derivative thereof as a disinfectant.
Dependencies are inferred from the claim text.